Lyra Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Lyra Therapeutics generated cash of -$63,304,000, which is less than the previous year. Cash used in financing activities reached the amount of $65,691,000 last year. Net change in cash is therefore -$10,197,000.
Cash Flow
| 2018 | -6.64M | -37K | 29.21M |
|---|---|---|---|
| 2019 | -13.75M | -211K | -115K |
| 2020 | -21.14M | -1.77M | 87.70M |
| 2021 | -25.82M | -3.38M | 359K |
| 2022 | -43.38M | -65.00M | 96.25M |
| 2023 | -63.30M | -12.58M | 65.69M |
LYRA Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 33.94M | 46.07M | 74.92M | 10.13M | 24.21M | 1.68M |
Operating activities | ||||||
Net income | -62.68M | -55.27M | -43.51M | -22.12M | -16.30M | -6.02M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 278K | 1.06M | 1.00M | 95K | 27K | 82K |
Stock-based compensation expense | 5.88M | 5.44M | 2.77M | 1.81M | 244K | 406K |
| Deferred income tax benefit | 5.88M | 5.44M | 2.77M | 1.81M | 244K | 406K |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 450K | -2.41M | 2.35M | 345K | -205K | 134K |
Cash generated by operating activities | -63.30M | -43.38M | -25.82M | -21.14M | -13.75M | -6.64M |
Investing activities | ||||||
Purchases Of Investments | -122.42M | -64.84M | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -1.04M | -164K | -3.38M | -1.77M | -211K | -37K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -12.58M | -65.00M | -3.38M | -1.77M | -211K | -37K |
Financing activities | ||||||
Common Stock Issued | 69.24M | 100.49M | 604K | 59.89M | 111K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 65.69M | 96.25M | 359K | 87.70M | -115K | 29.21M |
Net Change In Cash | -10.19M | -12.13M | -28.84M | 64.78M | -14.08M | 22.53M |
Cash at end of period | 23.74M | 33.94M | 46.07M | 74.92M | 10.13M | 24.21M |
| Data source | Data source | Data source | Data source |